AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34275768 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate 50 mg once a day for 6 months
Number of subjects: 162
Study 34275768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 33834509 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-MtRobin method
Number of subjects: 0
Study 33461268 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-Traumatic Growth (PTG) dimensions: personal mental strength, interpersonal relations, new possibilities, appreciation of life
Number of subjects: 277
Study 33461268 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-Traumatic Stress Disorder (PTSD) symptoms and reactions
Number of subjects: 277
Study 35438179 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaporized CBD-dominant cannabis
Number of subjects: 18
Study 35438179 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaporized CBD
Number of subjects: 18
Study 35438179 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral CBD
Number of subjects: 18
Study 35438179 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidiolex (oral formulation)
Number of subjects: 18
Study 35438179 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule (oral formulation)
Number of subjects: 18
Study 35438179 — intervention group
Group type: EXPERIMENTAL
Intervention: Syrup (oral formulation)
Number of subjects: 18
Study 35438179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 33845158 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve repair plus GDMT
Number of subjects: 565
Study 33845158 — intervention group
Group type: COMPARATOR
Intervention: GDMT alone
Number of subjects: 565
Study 32426882 — intervention group
Group type: EXPERIMENTAL
Intervention: YCF supplemented with 2'‐fucosyllactose (2'‐FL)
Number of subjects: 461
Study 32426882 — intervention group
Group type: EXPERIMENTAL
Intervention: YCF supplemented with milk fat and intact bioactive proteins, and 2'‐FL at levels found in breast milk
Number of subjects: 461
Study 32426882 — intervention group
Group type: EXPERIMENTAL
Intervention: YCF with bioactive proteins at lower levels than breast milk
Number of subjects: 461
Study 32426882 — intervention group
Group type: COMPARATOR
Intervention: YCF-Ref (standard milk formula)
Number of subjects: 461
Study 35013377 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave Ablation (MWA)
Number of subjects: 82
Study 35013377 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency Ablation (RFA)
Number of subjects: 82
Study 34010805 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Selected Exercise Intensity (SEI)
Number of subjects: 37
Study 34010805 — intervention group
Group type: COMPARATOR
Intervention: Predetermined Exercise Intensity (PEI)
Number of subjects: 37
Study 36419071 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient management (OG)
Number of subjects: 97
Study 36419071 — intervention group
Group type: COMPARATOR
Intervention: Standard care (HG)
Number of subjects: 97
Study 33251538 — intervention group
Group type: EXPERIMENTAL
Intervention: Active music engagement
Number of subjects: 48
Study 33251538 — intervention group
Group type: EXPERIMENTAL
Intervention: Live patient-selected music
Number of subjects: 48
Study 33251538 — intervention group
Group type: EXPERIMENTAL
Intervention: Music-assisted relaxation
Number of subjects: 48
Study 34423560 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized healing abutments (CA)
Number of subjects: 28
Study 34423560 — intervention group
Group type: COMPARATOR
Intervention: Collagen matrix (CM)
Number of subjects: 28
Study 34423560 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CA and CM
Number of subjects: 28
Study 35363951 — intervention group
Group type: EXPERIMENTAL
Intervention: Active-treatment group (antihypertensive medications recommended for use in pregnancy)
Number of subjects: 2408
Study 35363951 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment unless severe hypertension developed)
Number of subjects: 2408
Study 35363951 — intervention group
Group type: EXPERIMENTAL
Intervention: Active-treatment group
Number of subjects: 2408
Study 35363951 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2408
Study 34145478 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-powder polishing (APP)
Number of subjects: 23
Study 34145478 — intervention group
Group type: COMPARATOR
Intervention: Rubber-cup polishing (RCP)
Number of subjects: 23
Study 33153515 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional intelligence intervention (10 sessions, 90 min each)
Number of subjects: 111
Study 33153515 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 111
Study 33686102 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial static magnetic stimulation (tSMS) over the left primary motor cortex (M1) for 30 minutes
Number of subjects: 0
Study 36309168 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60
Study 36309168 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 60
Study 33711180 — intervention group
Group type: EXPERIMENTAL
Intervention: Felcisetrag 0.1 mg
Number of subjects: 36
Study 33711180 — intervention group
Group type: EXPERIMENTAL
Intervention: Felcisetrag 0.3 mg
Number of subjects: 36
Study 33711180 — intervention group
Group type: EXPERIMENTAL
Intervention: Felcisetrag 1.0 mg
Number of subjects: 36
Study 33711180 — intervention group
Group type: EXPERIMENTAL
Intervention: Felcisetrag (all doses)
Number of subjects: 36
Study 33711180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 32308187 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed nutritional messages
Number of subjects: 161
Study 32308187 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed nutritional messages
Number of subjects: 161
Study 32308187 — intervention group
Group type: COMPARATOR
Intervention: Control group (no food message)
Number of subjects: 161
Study 33952812 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10mg/day)
Number of subjects: 31
Study 33952812 — intervention group
Group type: COMPARATOR
Intervention: Dietary management
Number of subjects: 31
Study 32090491 — intervention group
Group type: EXPERIMENTAL
Intervention: ARCTIC trial (tight control cohort targeting stringent remission)
Number of subjects: 519
Study 32090491 — intervention group
Group type: COMPARATOR
Intervention: NOR-VEAC observational study (looser definition of remission)
Number of subjects: 519
Study 36126241 — intervention group
Group type: EXPERIMENTAL
Intervention: Evobrutinib 25 mg once-daily (q.d.)
Number of subjects: 207
Study 36126241 — intervention group
Group type: EXPERIMENTAL
Intervention: Evobrutinib 75 mg once-daily (q.d.)
Number of subjects: 207
Study 36126241 — intervention group
Group type: EXPERIMENTAL
Intervention: Evobrutinib 75 mg twice-daily (b.i.d.)
Number of subjects: 207
Study 36126241 — intervention group
Group type: EXPERIMENTAL
Intervention: Evobrutinib 45 mg twice-daily (b.i.d.) with food
Number of subjects: 207
Study 36126241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 33114782 — intervention group
Group type: EXPERIMENTAL
Intervention: Machines only
Number of subjects: 36
Study 33114782 — intervention group
Group type: EXPERIMENTAL
Intervention: Free weights only
Number of subjects: 36
Study 33114782 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from machines to free weights
Number of subjects: 36
Study 35819090 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspension Training System (STS)
Number of subjects: 36
Study 35819090 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric-Isotonic (ISoM-ISoT) exercises
Number of subjects: 36
Study 35819090 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal life)
Number of subjects: 36
Study 35422023 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs) including citalopram, paroxetine, and sertraline
Number of subjects: 11387
Study 35422023 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 11387
Study 35422023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11387
Study 32705343 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop Ileostomy (LI)
Number of subjects: 148
Study 32705343 — intervention group
Group type: COMPARATOR
Intervention: Loop Colostomy (LC)
Number of subjects: 148
Study 35253598 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole 200 mg
Number of subjects: 183
Study 35253598 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 200 mg + Gentian Violet
Number of subjects: 183
Study 33337112 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke characteristics (backswing and forward motion duration)
Number of subjects: 42
Study 33337112 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball speed
Number of subjects: 42
Study 33337112 — intervention group
Group type: EXPERIMENTAL
Intervention: Spin speed
Number of subjects: 42
Study 33337112 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement of the stroke
Number of subjects: 42
Study 35764236 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 403
Study 35764236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 403
Study 34258468 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis 500 mg twice a day for 3 months
Number of subjects: 48
Study 34258468 — intervention group
Group type: COMPARATOR
Intervention: Placebo 500 mg twice a day for 3 months
Number of subjects: 48
Study 32690834 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (topical + systemic, 800 mg/day)
Number of subjects: 60
Study 32690834 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (topical + systemic, 950 mg/day)
Number of subjects: 60
Study 32690834 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (green tea extract + curcumin)
Number of subjects: 60
Study 35977666 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% FF‐EODF
Number of subjects: 28
Study 35977666 — intervention group
Group type: EXPERIMENTAL
Intervention: FF‐EODF
Number of subjects: 28
Study 35977666 — intervention group
Group type: COMPARATOR
Intervention: EODF
Number of subjects: 28
Study 35977666 — intervention group
Group type: EXPERIMENTAL
Intervention: FF supplementation
Number of subjects: 28
Study 34212465 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 576
Study 32357805 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable resistance (WR) of 1%, 2%, and 3% body mass (BM)
Number of subjects: 14
Study 32357805 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable resistance (WR) of ≥2% body mass (BM)
Number of subjects: 14
Study 32357805 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable resistance (WR) of 3% body mass (BM)
Number of subjects: 14
Study 32357805 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable resistance (WR)
Number of subjects: 14
Study 33533873 — intervention group
Group type: EXPERIMENTAL
Intervention: TMVr plus GDMT
Number of subjects: 548
Study 33533873 — intervention group
Group type: COMPARATOR
Intervention: GDMT alone
Number of subjects: 548
Study 36339547 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (10–25 μg/kg) combined with a fixed low dose of midazolam
Number of subjects: 0
Study 36339547 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (fixed low dose)
Number of subjects: 0
Study 34053272 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based exercise educational care management system
Number of subjects: 452
Study 34053272 — intervention group
Group type: COMPARATOR
Intervention: Traditional in-person physiotherapy rehabilitation model
Number of subjects: 452
Study 32125434 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-Conjugate vaccine
Number of subjects: 1146
Study 32125434 — intervention group
Group type: COMPARATOR
Intervention: MenACWY-Polysaccharide vaccine
Number of subjects: 1146
Study 32125434 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines (MenACWY-Conjugate and MenACWY-Polysaccharide)
Number of subjects: 1146
Study 34857382 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green group
Number of subjects: 38
Study 34857382 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study 33909855 — intervention group
Group type: EXPERIMENTAL
Intervention: G11914A variant in the NADPH gene
Number of subjects: 88
Study 33909855 — intervention group
Group type: COMPARATOR
Intervention: Control group (NOT_FINISHED, 'NF')
Number of subjects: 88
Study 34873992 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric Training (PT) - two weekly sessions for eight weeks
Number of subjects: 28
Study 34873992 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 28
Study 33267860 — intervention group
Group type: EXPERIMENTAL
Intervention: Microenterprise intervention (text messages on job openings, educational sessions, mentoring, start-up grant, business and HIV prevention text messages)
Number of subjects: 38
Study 33267860 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (text messages on job openings only)
Number of subjects: 38
Study 35944568 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard tibia TKA
Number of subjects: 264
Study 35944568 — intervention group
Group type: EXPERIMENTAL
Intervention: Stemmed tibia TKA
Number of subjects: 264
Study 35944568 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (in-group analysis)
Number of subjects: 264
Study 33595625 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial CT scan measurements every 6 months for 2 years
Number of subjects: 254
Study 33595625 — intervention group
Group type: COMPARATOR
Intervention: Maximum transverse diameter of at least 4.25 cm
Number of subjects: 254
Study 32527707 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided HIFU ablation
Number of subjects: 374
Study 32527707 — intervention group
Group type: COMPARATOR
Intervention: Uterus-sparing surgery
Number of subjects: 374
Study 35761453 — intervention group
Group type: COMPARATOR
Intervention: CT density measurement (Hounsfield Units) for grade 0 (no otosclerosis)
Number of subjects: 78
Study 35761453 — intervention group
Group type: COMPARATOR
Intervention: CT density measurement (Hounsfield Units) for grade 1 (inactive otosclerosis)
Number of subjects: 78
Study 35761453 — intervention group
Group type: COMPARATOR
Intervention: CT density measurement (Hounsfield Units) for grades 2 and 3 (mixed/active otosclerosis)
Number of subjects: 78
Study 35761453 — intervention group
Group type: EXPERIMENTAL
Intervention: CT density measurement
Number of subjects: 78
Study 34974559 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrument-assisted soft tissue mobilization along with routine physical therapy
Number of subjects: 60
Study 34974559 — intervention group
Group type: COMPARATOR
Intervention: Routine physical therapy
Number of subjects: 60
Study 34974559 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques (Instrument-assisted soft tissue mobilization and Routine physical therapy)
Number of subjects: 60
Study 34013559 — intervention group
Group type: EXPERIMENTAL
Intervention: Adlerian therapy (AT)
Number of subjects: 60
Study 34013559 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution-focused brief therapy (SFBT)
Number of subjects: 60
Study 34013559 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 60
Study 33118194 — intervention group
Group type: EXPERIMENTAL
Intervention: PPE 25 mg/kg body weight
Number of subjects: 24
Study 33118194 — intervention group
Group type: EXPERIMENTAL
Intervention: PPE 50 mg/kg body weight
Number of subjects: 24
Study 33118194 — intervention group
Group type: COMPARATOR
Intervention: Control (water only)
Number of subjects: 24
Study 33118194 — intervention group
Group type: EXPERIMENTAL
Intervention: PPE treatments (both doses)
Number of subjects: 24
Study 34674276 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resin adhesive with polytetrafluoroethylene tape and composite resin
Number of subjects: 20
Study 34674276 — intervention group
Group type: COMPARATOR
Intervention: Composite resin alone (without adhesive)
Number of subjects: 20
Study 32764397 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Dynamic Resistance Exercise (HIT‐RT)
Number of subjects: 43
Study 32764397 — intervention group
Group type: COMPARATOR
Intervention: Control group (non‐training)
Number of subjects: 43
Study 35877104 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-Modifying Treatments (DMTs)
Number of subjects: 665
Study 32061121 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone call reminders
Number of subjects: 0
Study 33331902 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoxia (minimum fraction of inspired oxygen of 0.35)
Number of subjects: 100
Study 33331902 — intervention group
Group type: COMPARATOR
Intervention: Hyperoxia (fraction of inspired oxygen of 1.0)
Number of subjects: 100
Study 33331902 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoxia
Number of subjects: 100
Study 33331902 — intervention group
Group type: COMPARATOR
Intervention: Hyperoxia
Number of subjects: 100
Study 33331902 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoxia and Hyperoxia
Number of subjects: 100
Study 32958026 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised physiotherapy intervention
Number of subjects: 0
Study 32958026 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-individualised physiotherapy intervention
Number of subjects: 0
Study 32958026 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control group)
Number of subjects: 0
Study 34358723 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-Virgin Olive Oil (EVOO) 25 mL/d for 52 days
Number of subjects: 73
Study 34358723 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil (control) 25 mL/d for 52 days
Number of subjects: 73
Study 34358723 — intervention group
Group type: EXPERIMENTAL
Intervention: EVOO
Number of subjects: 73
Study 34358723 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil (control)
Number of subjects: 73
Study 33386840 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety attitude
Number of subjects: 320
Study 33386840 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety climate (mediating role)
Number of subjects: 320
Study 32657164 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod (FTY720) for less than six months (Group 1)
Number of subjects: 80
Study 32657164 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod (FTY720) for longer than six months (Group 2)
Number of subjects: 80
Study 32657164 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 80
Study 32520410 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR247799 (2.5–37.5 mg single dose)
Number of subjects: 0
Study 32520410 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR247799 (0.5–15 mg once-daily for 2 weeks)
Number of subjects: 0
Study 32520410 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR247799 (10 mg)
Number of subjects: 0
Study 32520410 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR247799 (≤5 mg)
Number of subjects: 0
Study 32520410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32293033 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIME (4 weeks)
Number of subjects: 19
Study 32293033 — intervention group
Group type: COMPARATOR
Intervention: COMBO (4 weeks)
Number of subjects: 19
Study 35699623 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI0562 + durvalumab (7.5 mg MEDI0562 + 1,500 mg durvalumab)
Number of subjects: 58
Study 35699623 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI0562 + tremelimumab (22.5 mg MEDI0562 + 225 mg tremelimumab)
Number of subjects: 58
Study 35699623 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI0562 + durvalumab or tremelimumab
Number of subjects: 58
Study 34822784 — intervention group
Group type: EXPERIMENTAL
Intervention: HTL9936, a muscarinic M1 receptor agonist, designed for cognitive loss in Alzheimer's disease.
Number of subjects: 0
Study 35287100 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver group
Number of subjects: 15
Study 35287100 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion effects group
Number of subjects: 15
Study 35287100 — intervention group
Group type: EXPERIMENTAL
Intervention: Different thickness cohorts
Number of subjects: 15
Study 35287100 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest group
Number of subjects: 15
Study 35287100 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation group
Number of subjects: 15
Study 35287100 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall radiomics features
Number of subjects: 15
Study 35287100 — intervention group
Group type: EXPERIMENTAL
Intervention: Beam on condition
Number of subjects: 15
Study 35287100 — intervention group
Group type: EXPERIMENTAL
Intervention: Shape features
Number of subjects: 15
Study 32691164 — intervention group
Group type: COMPARATOR
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 0
Study 32691164 — intervention group
Group type: COMPARATOR
Intervention: Guanfacine extended release (GXR)
Number of subjects: 0
Study 32691164 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline WFIRS‐P scores
Number of subjects: 0
Study 35363780 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (source reduction intervention)
Number of subjects: 520
Study 35363780 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 520
Study 33735465 — intervention group
Group type: EXPERIMENTAL
Intervention: BFRRE to failure (Failure)
Number of subjects: 17
Study 33735465 — intervention group
Group type: COMPARATOR
Intervention: BFRRE not to failure (Non-failure)
Number of subjects: 17
Study 32897014 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenazopyridine 200 mg administered 20 minutes before cystoscopy and then 200 mg every 8 hours (total three doses) with lidocaine gel
Number of subjects: 97
Study 32897014 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenazopyridine with lidocaine gel
Number of subjects: 97
Study 32897014 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine gel
Number of subjects: 97
Study 33428636 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention villages
Number of subjects: 394
Study 33428636 — intervention group
Group type: COMPARATOR
Intervention: Control villages
Number of subjects: 394